Rachel Burga

Rachel Burga

Auto-generated profile, based on publicly available information

Rachel Burga

Obsidian Therapeutics, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CLCatalina Lee-Chang
Catalina Lee-Chang
JMJason Michael Miska
Jason Michael Miska
DHDavid Hou
David Hou
ARAida Rashidi
Aida Rashidi
PZPeng Zhang
Peng Zhang
MLMaciej Lesniak
Maciej Lesniak
Immunotherapy has revolutionized the treatment of many tumors. However, most glioblastoma (GBM) patients have not, so far, benefited from such successes. With the goal of exploring ways to boost anti-GBM immunity, we developed a B cell–based vaccine (BVax) that consists of 4-1BBL+ B cells activated with CD40 agonism and IFNγ stimulation. BVax migrates to key secondary lymphoid organs and is proficient at antigen cross-presentation, which promotes both the survival and the functionality of CD8+ T cells. A combination of radiation, BVax, and PD-L1 blockade conferred tumor eradication in 80% of treated tumor-bearing animals. This treatment elicited immunological memory that prevented the growth of new tumors upon subsequent reinjection in cured mice. GBM patient–derived BVax was successful in activating autologous CD8+ T cells; these T cells showed a strong ability to kill autologous glioma cells. Our study provides an efficient alternative to current immunotherapeutic approaches that can be readily translated to the clinic.

24 April 2025 in Molecular Therapy
Verified
Journal Article
Open access
RBRachel A. Burga
Rachel A. Burga
BABulent Arman Aksoy
Bulent Arman Aksoy
ZAZheng Ao
Zheng Ao
JTJeremy H. Tchaicha
Jeremy H. Tchaicha
DSDhruv K. Sethi
Dhruv K. Sethi
JMJan ter Meulen
Jan ter Meulen
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) has demonstrated great potential for patients with treatment-refractory metastatic melanoma. However, the need for interleukin 2 (IL2) co-administration during TIL cell therapy limits patient eligibility and restricts treatment to intensive care units due to the risk of severe side effects. Instead, engineering TIL with membrane-bound interleukin 15 (mbIL15) has the potential to promote TIL expansion, antitumor activity, and persistence of CD8+ T cells, without the use of IL2. cytoTIL15™ cells express mbIL15 fused to a drug-responsive domain (DRD) that is regulated by the FDA-approved small-molecule drug acetazolamide (ACZ). As such, cytoTIL15 cells are manufactured with ACZ instead of IL2, in the presence of engineered feeder cells. The cytoTIL15 cell product exhibits ACZ dose-dependent expansion and persistence in vitro and in vivo and potent tumor-killing activity in human melanoma models in the absence of IL2. In patient-derived xenograft (PDX) tumors, spatial profiling revealed infiltrating cytoTIL15 cells to be highly cytotoxic and less exhausted than non-engineered TIL. This novel platform creates a powerful, IL2-free TIL cell therapy with a potentially improved tolerability and safety profile, while allowing individualized pharmacologic regulation of the TIL product.

20 February 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy is showing promising efficacy against immunologically “hot” tumors such as melanoma, cervical cancer, and renal cancer. However, generation of tumoricidal TILs from “cold” tumors with a low tumor mutational burden, such as many sarcoma types, poses a challenge due to limited infiltration of the tumor microenvironment (TME) with lymphocytes, low frequencies of tumor antigen–specific, high-affinity T cells, and incompletely understood mechanisms of immune-resistance prevailing in the TME. Here, we report the successful generation and expansion of TILs engineered with regulatable, membrane-bound IL15 (cytoTIL15 cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2. Comprehensive spatial profiling of the TME revealed ubiquitous collagen and myeloid infiltration as major resistance mechanisms, whereas lymphocytic infiltration was largely restricted to peripheral regions of the tumors, a relevant consideration when sampling these tumors for TIL harvest. Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
RBRachel Burga
Rachel Burga
ZAZheng Ao
Zheng Ao
AAArman Aksoy
Arman Aksoy
SLScott Lajoie
Scott Lajoie
KPKyle Pedro
Kyle Pedro
MKMithun Khattar
Mithun Khattar
Background CytoTIL15® therapy is an IL2-independent, engineered TIL product which allows pharmacological control of membrane-bound IL15 (mbIL15). We have previously shown that cytoTIL15® TILs demonstrate enhanced persistence and anti-tumor efficacy in a human allogeneic melanoma PDX model. Here we use digital spatial profiling and single cell sequencing to characterize the RNA expression profile and phenotypic markers of tumor infiltrating immune cells as well as tumor cells in this model and compare the results to unengineered, IL2-dependent TIL. Methods cytoTIL15® therapy contains TILs engineered with mbIL15 under the control of a carbonic-anhydrase-2 drug responsive domain, regulated by the ligand acetazolamide (ACZ). cytoTIL15® cells were generated from human melanomas through a proprietary rapid expansion process. Expanded TILs were phenotyped and assayed for in vitro polyfunctionality, cytotoxicity, and frequency of tumor-associated antigen-specific TCR. In vivo phenotype and anti-tumor functionality was examined through adoptive transfer of TILs into NSG mice bearing subcutaneous, HLA-matched, patient-derived-xenograft (PDX) tumors expressing melanoma-associated antigen MART-1, in IACUC approved animal studies. Tumors, spleen, bone marrow, and blood were harvested 14-21 days following adoptive cell transfer and assessed by flow cytometry, GeoMx digital spatial profiling, and single cell sequencing for characterization of TIL and the tumor microenvironment (TME). Results cytoTIL15® cells demonstrated enrichment and reactivity for melanoma antigen-specific TCRs, while maintaining TCRβ diversity. Fifteen days post-ACT, tumors from animals treated with cytoTIL15® cells exhibited significantly (p=0.0175) higher frequency (3.4-fold) of TILs, in which MART-1 tetramer positive cells demonstrated increased T-cell factor 1 (TCF-1) and CD69 expression, and secreted significantly greater amounts of IFNγ and TNFα cytokines into the TME, compared to unengineered TILs with IL2. In addition, cytoTIL15® TILs had a distinct differential gene expression profile, demonstrating an increase in effector genes such as IL2RB, GZMB, GNLY and CCL5 and reduction in exhaustion-related genes such as EOMES. cytoTIL15® cells accumulating in the bone marrow exhibited a lower frequency of CD39+ terminally differentiated CD8+ T cells, while maintaining higher levels of memory phenotype makers. Conclusions In this allogeneic melanoma PDX model, cytoTIL15® cells showed a distinct profile of RNA expression and phenotypic markers, consistent with their increased persistence and anti-tumor efficacy. Interestingly, the subpopulation of cytoTIL15® cells reactive to tumor-associated antigen MART-1 displayed increased expression of TCF-1, which in melanoma patients has been associated with responses to immune checkpoint blockade, in addition to progression-free and overall survival. Ethics Approval All animal studies were IACUC approved.

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Figure S2: Gating strategy for REP phenotyping

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Figure S3: Gating strategy for memory phenotyping.